Aim-traded pharma group Chi-Med (HCM) made strong progress on its oncology pipeline during the first half, having "minimised" the effects of the coronavirus pandemic so far. Indeed, in May, the group submitted a new drug application (NDA) to China’s National Medical Products Association for ‘savolitinib’ as a treatment for non-small-cell lung cancer. It also progressed an NDA submitted last November for ‘surufatinib’ in patients with non-pancreatic neuroendocrine tumours (NETs), as well as submitting a further NDA for the usage of the same drug in pancreatic NETs.
Together with its already-approved drug ‘fruquintinib’, chief executive Christian Hogg notes that Chi-Med now has “three oncology assets to launch into the China market” – offering up “a really solid platform to build out our commercial organisation and our business”. It helps that the group is taking over all sales and marketing activities for fruquintinib in China from partner company Eli Lilly.